Waters and Sartorius Enter Partnership to Improve Bioprocessing Analysis

Waters and Sartorius announced on Oct. 27, 2021, that they would partner to provide bioprocess experts with direct access to mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development. The two companies will implement Waters’ BioAccord Liquid Chromatography (LC)–MS System as a new bioprocess analyzer for Sartorius' Ambr multi-parallel bioreactor systems.

According to the press release, when combined with Waters’ LC–MS system, the speed and accuracy of Sartorius’ bioreactor will be significantly increased in tasks such as clone selection and bioprocess optimization. The companies hope to use this combination to decrease tasks that can take over a month to two days or less while providing more control to bioprocess scientists in obtaining MS data for drug substance and cell culture media samples.

“Waters and Sartorius share a commitment to biopharmaceutical customers to solve their problems with the very best process and analytical tools,” said Davy Petit, senior director of Global Pharmaceutical and Biomedical Research Business, Waters, in the press release. “Clone selection and process development can benefit significantly from at-line versatile mass spectrometry data, which can help bioprocess engineers accelerate workflows and increase confidence in making critical decisions. The combination of our technology in the hands of bioprocess scientists, alongside the well-established Sartorius Ambr bioreactor systems installed-base, can significantly reduce the development timeline for delivery of medicines and vaccines.”

“The combination of Ambr and the easy-to-use at-line Waters BioAccord LC–MS System will save bioprocess scientists substantial time and accelerate clone selection and upstream process development,” said Mario Becker, head of Product Management Cell Culture Technologies at Sartorius, in the press release. “The closer we can bring fundamentally important MS data to the point where it is needed, and the more Ambr samples that can be tested for quality attributes, the better we can provide bioprocess scientists a more complete picture of drug product quality at any point during cell-line, media, and process development. Eventually, we can envisage such process control, monitoring, and product quality testing being fully integrated into the manufacturing environment.”

Source: Waters